Folic acid intravenous - Endocyte

Drug Profile

Folic acid intravenous - Endocyte

Alternative Names: IV folic acid - Endocyte; Neocepri; Technetium Tc99m etarfolatide companion diagnostic - Endocyte

Latest Information Update: 21 May 2014

Price : $50

At a glance

  • Originator Endocyte
  • Class Antianaemics; Antidotes; Chemoprotectants; Chemosensitisers; Pterins; Small molecules; Vitamins
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Ovarian cancer

Most Recent Events

  • 16 May 2014 Regulatory submission withdrawn for Diagnostic imaging (patients with folate receptor-positive ovarian cancer) in European Union (IV) ,
  • 16 May 2014 Regulatory submission withdrawn for Ovarian cancer (diagnosis of patients with folate receptor-positive ovarian cancer) in European Union (IV) ,
  • 20 Mar 2014 Preregistration for Ovarian cancer (diagnosis of patients with folate receptor-positive ovarian cancer) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top